Showing 93 results
- https://prod1.novartis.com/news/media-releases/novartis-data-asco-and-eha-reinforce-companys-commitment-reimagining-cancerResults from the Kisqali® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be…
- https://prod1.novartis.com/news/media-releases/novartis-presents-new-data-21-medicines-and-11-investigational-compounds-asco-and-ehaOverall survival data for Tafinlar® and Mekinist® combination to be presented in metastatic BRAF V600E/K mutation-positive cutaneous melanoma New data for Zykadia® in ALK+ non-small cell lung…
- https://prod1.novartis.com/news/media-releases/novartis-data-asco-icml-and-eha-meetings-demonstrate-meaningful-advancements-cancer-careUpdated analyses from the Kisqali® pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be…
- https://prod1.novartis.com/news/media-releases/novartis-present-pivotal-data-hematologic-and-solid-tumor-cancers-2016-asco-annual-meetingFirst data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna® both in front-line and second-line following Glivec®* First genomic analysis and 3-year…
- https://prod1.novartis.com/news/media-releases/novartis-data-asco-and-eha-showcase-latest-oncology-research-and-innovation-including-breast-and-prostate-cancerLatest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new…
- https://prod1.novartis.com/news/media-releases/novartis-data-asco-and-eha-demonstrate-novel-approaches-reimagining-medicine-cancer-and-serious-blood-disordersOverall survival results from MONALEESA-7 with Kisqali® (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary results…
- https://prod1.novartis.com/news/media-releases/novartis-presents-new-data-asco-zykadia-and-combination-tafinlar-and-mekinist-certain-nsclc-patients-unmet-needsIn Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+ NSCLC; comparable overall response in those with or without brain metastases[1],[2] Tafinlar (dabrafenib) and Mekinist…
- https://prod1.novartis.com/news/media-releases/novartis-data-asco-and-eha-showcase-bold-approaches-reimagine-cancer-and-blood-disorders-through-multiple-therapeutic-platformsNew Kisqali® (ribociclib)* overall survival subgroup analysis in HR+/HER2- advanced breast cancer (ABC) and additional Piqray® (alpelisib) data in patients in HR+/HER2- ABC patients with a PIK3CA…
- https://prod1.novartis.com/news/media-releases/novartis-unveil-new-data-asco-and-eha-from-its-robust-portfolio-including-overall-survival-prostate-and-breast-cancerOverall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be…
- https://prod1.novartis.com/news/media-releases/novartis-present-new-data-across-oncology-portfolio-including-kisqali-phase-iii-natalee-trial-early-breast-cancer-ascoPrimary analysis of NATALEE, the first and only positive Phase III study of a CDK4/6 inhibitor in a broad population of patients with stage II and III HR+/HER2- early breast cancer at risk of…